Curated news and analysis on clinical trials, drug approvals, and medical research.
The global pancreatic cancer precision medicine market is projected to grow from US$ 610 million in 2024 to US$ 2,467.83 million by 2033 at a 16.8% CAGR, driven by advances in targeted therapies, genomic diagnostics, and liquid biopsies.
Nuclera and leadXpro announced a scientific partnership combining rapid multiplex membrane protein screening with AI/ML-driven construct design to accelerate structure-based drug discovery for challenging membrane protein targets.
BioNxt Solutions Inc. receives European Patent No. 4539857 for its proprietary sublingual cladribine oral thin film drug delivery technology, providing protection across up to 39 European Patent Convention states through at least June 14, 2043.
The European Commission has approved GSK's Exdensur (depemokimab) as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, offering twice-yearly dosing based on positive phase 3 trial results.
The CBSE Class 12 Biotechnology Board Examination was conducted on February 17, 2026, as part of the annual board examinations. The exam was held for 70 marks with a moderate difficulty level reported by students.
The Consolidated Appropriations Act of 2026 extends the FDA's authority to award rare pediatric disease priority review vouchers through September 30, 2029, restoring a key incentive for developing therapies for rare pediatric diseases.
New clinical trial data show trastuzumab deruxtecan plus pertuzumab extends progression-free survival as first-line therapy, while MRI-guided treatment shortening reduces toxicity in neoadjuvant settings for HER2-positive breast cancer.
Scientists are developing blood tests that can detect cancer years before symptoms appear, including CRISPR-powered sensors and multi-cancer early detection tests that identify molecular warning signs in the bloodstream.
Researchers have identified a specific neurobiological link between age-related hearing loss and cognitive decline through a new biomarker called the Functional-Structural Ratio, which could help doctors predict dementia risk from brain scans.
Phase II trial finds adding gemcitabine to cisplatin does not improve outcomes in muscle-invasive bladder cancer, while separate study shows gemcitabine-lobaplatin interventional embolization benefits advanced cervical cancer patients.
Indian pharmaceutical companies Sun Pharma and Glenmark are integrating AI into drug discovery to reduce development timelines and costs. Global pharma AI investment reached $6.93 billion last year and is projected to hit $16.5 billion by 2034.
Merck secures regulatory approvals for Keytruda in ovarian cancer and subcutaneous formulation in Canada, while launching AI-driven drug discovery partnership with Mayo Clinic targeting high-need therapeutic areas.
Myriad Genetics will release its fourth quarter and full year 2025 financial results on February 23, 2026 after market close, followed by an earnings conference call at 4:30 pm ET.
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
MIT chemical engineers developed a large language model that optimizes codon sequences for protein production in industrial yeast, boosting efficiency for six proteins including human growth hormone and cancer antibodies.
The provided source articles lack sufficient accessible factual content for synthesis. One article is inaccessible, another covers unrelated stock performance topics, and the third concerns a different company entirely.
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
The FDA agreed to review Moderna's mRNA-based flu vaccine after initially refusing, accepting a split regulatory approach with traditional approval for ages 50-64 and accelerated approval for 65 and older. Decision date set for August 5, 2026.
Eli Lilly reported Q4 2025 EPS of $7.54 versus $6.67 expected and projected 2026 revenue of $80-83 billion. The company's GLP-1 drugs Mounjaro and Zepbound drove growth with revenues surging over 110%.
Sygnature Discovery announced a strategic brand relaunch on February 16, 2026, positioning itself as the only CRO offering full DMTA capabilities under one roof in both North America and Europe.
